MCID: MYL075
MIFTS: 52

Myelodysplastic/myeloproliferative Neoplasm

Categories: Blood diseases, Cancer diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Myelodysplastic/myeloproliferative Neoplasm

MalaCards integrated aliases for Myelodysplastic/myeloproliferative Neoplasm:

Name: Myelodysplastic/myeloproliferative Neoplasm 11 19 14 36 16
Myelodysplastic-Myeloproliferative Diseases 43 71 75
Myelodysplastic/myeloproliferative Disease 19 58
Myeloproliferative/myelodysplastic Syndromes 11
Myelodysplastic Myeloproliferative Disease 11
Myelodysplastic Myeloproliferative Cancer 11

Characteristics:


Prevelance:

Myelodysplastic/myeloproliferative Disease: 1-9/1000000 (Europe) 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:4972
MeSH 43 D054437
NCIt 49 C27262
SNOMED-CT 68 445738007
ICD10 31 C94.6
MESH via Orphanet 44 D054437
UMLS via Orphanet 72 C1301355
Orphanet 58 ORPHA98275
UMLS 71 C1301355

Summaries for Myelodysplastic/myeloproliferative Neoplasm

GARD: 19 Myelodysplastic/myeloproliferative diseases are a group of diseases of the blood and bone marrow in which the bone marrow makes too many white blood cells. These disease have features of both myelodysplastic syndromes and myeloproliferative disorders. In myelodysplastic diseases, the blood stem cells do not mature into healthy red blood cells, white blood cells, or platelets and as a result, there are fewer of these healthy cells. In myeloproliferative diseases, a greater than normal number of blood stem cells develop into one or more types of blood cells and the total number of blood cells slowly increases. The 3 main types of Myelodysplastic/myeloproliferative diseases include chronic myelomonocytic leukemia (CMML); juvenile myelomonocytic leukemia (JMML); and atypical chronic myelogenous leukemia (aCML). When a Myelodysplastic/myeloproliferative disease does not match any of these types, it is called myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC). Symptoms of CMML and JMML may include fever, feeling tired and weight loss. Symptoms of aCML may include easy bruising or bleeding and feeling tired or weak.

MalaCards based summary: Myelodysplastic/myeloproliferative Neoplasm, also known as myelodysplastic-myeloproliferative diseases, is related to thrombocytosis and atypical chronic myeloid leukemia, bcr-abl1 negative. An important gene associated with Myelodysplastic/myeloproliferative Neoplasm is U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1), and among its related pathways/superpathways are Disease and ERK Signaling. The drugs Mercaptopurine and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, myeloid and bone, and related phenotypes are Decreased viability and Decreased substrate adherent cell growth

Disease Ontology: 11 A myeloid neoplasm that results in the overproduction of white blood cells.

Wikipedia: 75 Myelodysplastic-myeloproliferative diseases are a category of hematological malignancies which have... more...

Related Diseases for Myelodysplastic/myeloproliferative Neoplasm

Diseases related to Myelodysplastic/myeloproliferative Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 217)
# Related Disease Score Top Affiliating Genes
1 thrombocytosis 31.0 U2AF1 TET2 JAK2 CSF2 ASXL1
2 atypical chronic myeloid leukemia, bcr-abl1 negative 30.9 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PDGFRB
3 refractory anemia 30.7 TET2 ASXL1
4 cardiofaciocutaneous syndrome 1 30.4 PTPN11 NRAS NF1 HRAS
5 myeloid sarcoma 30.3 U2AF1 KIT FLT3
6 systemic mastocytosis with associated hematologic neoplasm 30.3 TET2 SRSF2 KIT ASXL1
7 li-fraumeni syndrome 30.3 U2AF1 NF1 LUC7L2 HRAS ETV6
8 acute erythroid leukemia 30.2 U2AF1 KIT JAK2 FLT3
9 juvenile myelomonocytic leukemia 30.1 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PTPN11
10 aplastic anemia 30.0 U2AF1 LUC7L2 FLT3 CSF3R CSF2 ASXL1
11 hypereosinophilic syndrome 30.0 PDGFRB KIT JAK2 CSF2 ABL1
12 acute megakaryocytic leukemia 30.0 U2AF1 KIT JAK2 FLT3 CSF2
13 chronic myelomonocytic leukemia 30.0 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PTPN11
14 mastocytosis 29.8 TET2 SRSF2 PDGFRB KIT JAK2 FLT3
15 systemic mastocytosis 29.8 U2AF1 TET2 SRSF2 PTPN11 PDGFRB KIT
16 thrombocytopenia 29.7 U2AF1 PTPN11 KIT JAK2 FLT3 ETV6
17 myeloproliferative neoplasm 29.5 U2AF1L4 U2AF1 TET2 SRSF2 PTPN11 PDGFRB
18 deficiency anemia 29.5 U2AF1 NRAS LUC7L2 KIT JAK2 FLT3
19 hematologic cancer 29.4 U2AF1 PTPN11 PDGFRB LUC7L2 KIT JAK2
20 leukemia, acute lymphoblastic 29.4 U2AF1 PTPN11 KIT JAK2 HRAS FLT3
21 myeloid leukemia 29.3 U2AF1 TET2 SETBP1 PTPN11 PDGFRB NRAS
22 myelofibrosis 29.3 U2AF1 TET2 SRSF2 SETBP1 PDGFRB KIT
23 acute promyelocytic leukemia 29.2 U2AF1 TET2 NRAS KIT HRAS FLT3
24 essential thrombocythemia 29.0 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 LUC7L2
25 leukemia 29.0 U2AF1 PTPN11 PDGFRB NRAS NF1 KIT
26 myelodysplastic syndrome 28.8 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PTPN11
27 leukemia, acute myeloid 28.7 U2AF1L4 U2AF1 TET2 SRSF2 SETBP1 PTPN11
28 leukemia, chronic myeloid 28.6 U2AF1 TET2 SETBP1 PTPN11 PDGFRB NRAS
29 aml with myelodysplasia-related features 11.4
30 unclassified myelodysplastic/myeloproliferative disease 11.4
31 acute myeloid leukemia with recurrent genetic anomaly 10.4
32 keratosis pilaris atrophicans faciei 10.4 PTPN11 NF1
33 childhood leptomeningeal melanoma 10.4 NRAS HRAS
34 b-lymphoblastic leukemia/lymphoma, bcr-abl1-like 10.4 JAK2 ABL1
35 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 10.3 FLT3 ABL1
36 lymphoblastic leukemia, acute, with lymphomatous features 10.3 JAK2 ABL1
37 melanocytic nevus syndrome, congenital 10.3 NRAS HRAS
38 wernicke encephalopathy 10.3 U2AF1 JAK2 ASXL1
39 intellectual developmental disorder, autosomal dominant 29 10.3 SETBP1 ABL1
40 vexas syndrome 10.3 U2AF1 TET2 ASXL1
41 chronic myelogenous leukemia, bcr-abl1 positive 10.3 NRAS CSF3R ABL1
42 stress polycythemia 10.3 JAK2 CSF3R ABL1
43 acute megakaryoblastic leukemia in down syndrome 10.3 SRSF2 PTPN11 NRAS
44 testicular spermatocytic seminoma 10.3 PTPN11 HRAS
45 meningeal melanomatosis 10.3 NRAS HRAS
46 pulmonic stenosis 10.3 PTPN11 NF1 HRAS
47 skin granular cell tumor 10.3 PTPN11 NF1
48 multiple enchondromatosis, maffucci type 10.3 TET2 PTPN11 NF1
49 noonan syndrome-like disorder with loose anagen hair 1 10.3 PTPN11 HRAS
50 primary hypereosinophilic syndrome 10.3 PDGFRB ETV6

Graphical network of the top 20 diseases related to Myelodysplastic/myeloproliferative Neoplasm:



Diseases related to Myelodysplastic/myeloproliferative Neoplasm

Symptoms & Phenotypes for Myelodysplastic/myeloproliferative Neoplasm

GenomeRNAi Phenotypes related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

25 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.84 HRAS
2 Decreased viability GR00055-A-2 10.84 HRAS
3 Decreased viability GR00173-A 10.84 FLT3
4 Decreased viability GR00221-A-1 10.84 ABL1 ETNK1 HRAS NF1 NRAS PDGFRB
5 Decreased viability GR00221-A-2 10.84 ABL1 ETNK1 HRAS JAK2 NF1
6 Decreased viability GR00221-A-3 10.84 ABL1 ETNK1 HRAS NRAS PDGFRB
7 Decreased viability GR00221-A-4 10.84 ETNK1 NF1 PDGFRB FLT3
8 Decreased viability GR00249-S 10.84 NF1
9 Decreased viability GR00301-A 10.84 KIT
10 Decreased viability GR00342-S-1 10.84 ABL1 ETNK1 PDGFRB
11 Decreased viability GR00342-S-2 10.84 ABL1
12 Decreased viability GR00342-S-3 10.84 ABL1
13 Decreased viability GR00386-A-1 10.84 NF1
14 no effect GR00402-S-1 10.19 ABL1 ASXL1 CSF2 CSF3R ETNK1 ETV6
15 no effect GR00402-S-2 10.19 ABL1 ASXL1 CSF2 CSF3R ETNK1 ETV6
16 Decreased substrate adherent cell growth GR00193-A-1 9.63 KIT
17 Decreased substrate adherent cell growth GR00193-A-2 9.63 ABL1 KIT
18 Decreased substrate adherent cell growth GR00193-A-4 9.63 ABL1 FLT3 KIT
19 Increased cell viability after pRB stimulation GR00230-A-1 9.13 ABL1 ETNK1 KIT

MGI Mouse Phenotypes related to Myelodysplastic/myeloproliferative Neoplasm:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.39 ABL1 ASXL1 CSF2 CSF3R ETV6 FLT3
2 homeostasis/metabolism MP:0005376 10.38 ABL1 ASXL1 CSF2 ETV6 FLT3 HRAS
3 growth/size/body region MP:0005378 10.37 ABL1 ASXL1 CSF2 CSF3R ETV6 FLT3
4 neoplasm MP:0002006 10.35 ASXL1 CSF2 ETV6 FLT3 HRAS JAK2
5 cellular MP:0005384 10.28 ABL1 ASXL1 CSF2 CSF3R ETV6 FLT3
6 normal MP:0002873 10.27 ABL1 ETV6 HRAS JAK2 KIT NF1
7 cardiovascular system MP:0005385 10.25 ABL1 CSF2 CSF3R ETV6 HRAS JAK2
8 immune system MP:0005387 10.22 ABL1 ASXL1 CSF2 CSF3R ETNK1 ETV6
9 liver/biliary system MP:0005370 10.2 ABL1 ASXL1 ETV6 JAK2 KIT NF1
10 behavior/neurological MP:0005386 10.18 ABL1 ASXL1 CSF2 HRAS JAK2 KIT
11 no phenotypic analysis MP:0003012 10.16 ETV6 FLT3 HRAS KIT NRAS PTPN11
12 embryo MP:0005380 10.15 ABL1 CSF2 ETV6 JAK2 KIT NF1
13 digestive/alimentary MP:0005381 10.13 ABL1 ASXL1 ETV6 HRAS KIT NF1
14 craniofacial MP:0005382 10.11 ABL1 ASXL1 CSF2 HRAS KIT NF1
15 hematopoietic system MP:0005397 10.09 ABL1 ASXL1 CSF2 CSF3R ETNK1 ETV6
16 skeleton MP:0005390 10.07 ABL1 ASXL1 CSF2 ETNK1 ETV6 FLT3
17 mortality/aging MP:0010768 9.91 ABL1 ASXL1 CSF2 CSF3R ETNK1 ETV6
18 integument MP:0010771 9.32 CSF2 ETV6 HRAS JAK2 KIT NF1

Drugs & Therapeutics for Myelodysplastic/myeloproliferative Neoplasm

Drugs for Myelodysplastic/myeloproliferative Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 317)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mercaptopurine Approved Phase 3 50-44-2 667490
2
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904
3
Daunorubicin Approved Phase 3 20830-81-3 30323
4
Hydroxyurea Approved Phase 3 127-07-1 3657
5
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
6
Idarubicin Approved Phase 3 58957-92-9 42890
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
9
Amitriptyline Approved Phase 3 50-48-6 2160
10
Baclofen Approved Phase 3 1134-47-0 2284
11
Ketamine Approved, Vet_approved Phase 3 6740-88-1, 1867-66-9 3821
12
Asparaginase Escherichia coli Approved, Investigational Phase 3 9015-68-3
13
Tioguanine Approved Phase 3 154-42-7 2723601
14
Hydrocortisone succinate Approved Phase 3 2203-97-6 3643
15
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
16
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 3640 5754
17
Mitoxantrone Approved, Investigational Phase 3 70476-82-3, 65271-80-9 4212
18
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
19
Ethinylestradiol Approved Phase 3 57-63-6 5991
20
Polyestradiol phosphate Approved Phase 3 28014-46-2
21
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
22
Moxifloxacin Approved, Investigational Phase 3 186826-86-8, 354812-41-2, 151096-09-2 152946
23
Isotretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4, 4759-48-2 5538 444795 5282379
24 Keratolytic Agents Phase 3
25 Analgesics, Non-Narcotic Phase 3
26 Dermatologic Agents Phase 3
27 Antiviral Agents Phase 3
28 Neurotransmitter Agents Phase 3
29 Psychotropic Drugs Phase 3
30 Antidepressive Agents Phase 3
31
Etoposide phosphate Phase 3 16760419
32 Adrenergic Agents Phase 3
33 Excitatory Amino Acid Antagonists Phase 3
34 Antidepressive Agents, Tricyclic Phase 3
35 Anesthetics, Dissociative Phase 3
36 GABA Agonists Phase 3
37 Ophthalmic Solutions Phase 3
38 Hydrocortisone-17-butyrate Phase 3
39 Hydrocortisone 17-butyrate 21-propionate Phase 3
40 Contraceptives, Oral Phase 3
41 Contraceptive Agents Phase 3
42 Estradiol 3-benzoate Phase 3
43 Estradiol 17 beta-cypionate Phase 3
44 Contraceptives, Oral, Combined Phase 3
45 Norgestimate, ethinyl estradiol drug combination Phase 3
46
Ginseng Investigational, Nutraceutical Phase 3 50647-08-0
47
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
48
Adenosine Approved, Investigational Phase 2 58-61-7 60961
49
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3 135329020
50
Ondansetron Approved, Withdrawn Phase 2 99614-02-5 4595

Interventional clinical trials:

(show top 50) (show all 230)
# Name Status NCT ID Phase Drugs
1 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
2 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
3 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
4 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
5 A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3 cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
6 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
7 A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201) Completed NCT00075816 Phase 3
8 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
9 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
10 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
11 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
12 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
13 The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
14 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
15 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery Completed NCT00782145 Phase 3
16 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
17 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
18 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
19 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
20 A Multiinstitutional Trial To Evaluate The Prophylactic Use Of NASA-Developed Light Emitting Diodes For The Prevention Of Oral Mucositis In Bone Marrow Transplant Patients Unknown status NCT00036712 Phase 2
21 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
22 A Phase II Study of and Oral Histone Deacytylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies Completed NCT00462605 Phase 2 entinostat;sargramostim
23 A Phase 2 Study of WEE1 Inhibition With AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome Completed NCT02666950 Phase 2 Cytarabine;WEE1 Inhibitor AZD1775
24 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
25 Phase II Study of Intravenous Ganciclovir Followed by Oral Ganciclovir in the Treatment of Reactivation of CMV Following Bone Marrow Transplant Completed NCT00530218 Phase 2 Ganciclovir
26 Phase I/II Study of Ruxolitinib Plus Decitabine in Patients With Post Myeloproliferative Neoplasm - Acute Myeloid Leukemia (AML) Completed NCT02257138 Phase 1, Phase 2 Decitabine;Ruxolitinib Phosphate
27 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
28 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
29 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
30 A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
31 Decidual Stromal Cells (DSC) in Treatment of Steroid-Refractory Graft-vs-host Disease in a Recipient of Matched Related Donor Allogeneic Hematopoietic Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm Completed NCT04926194 Phase 2
32 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
33 Conditioning for Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies Completed NCT01056614 Phase 2 fludarabine phosphate;busulfan;tacrolimus;methotrexate
34 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
35 Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial Completed NCT00096161 Phase 2 Cyclosporine;Mycophenolate Mofetil;Pentostatin
36 Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation Completed NCT01527045 Phase 2 Atorvastatin Calcium;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
37 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
38 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
39 A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
40 A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia Completed NCT01712308 Phase 2
41 Phase I/II Study of Tipifarnib [Zarnestra, Farnesyltransferase Inhibitor R115777 (NSC 702818)] in Patients With Myeloproliferative Disorders Completed NCT02210858 Phase 1, Phase 2 Tipifarnib
42 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
43 Pre-administration of Rabbit Antithymocyte Globulin to Optimize Donor T-Cell Engraftment Following Reduced Intensity Allogeneic Peripheral Blood Progenitor Cell Transplantation From Matched-Related Donors Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
44 A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML Completed NCT00425477 Phase 2 bexarotene
45 A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease Completed NCT00410657 Phase 2 methylprednisolone;prednisone
46 Therapy of Advanced Stage Myelodysplastic Syndrome (MDS) With Arsenic Trioxide Given in Combination With Etanercept: A Phase I/II Study Completed NCT00093366 Phase 1, Phase 2 arsenic trioxide
47 A Phase II Study of the Combination of Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-Versus-Host Disease Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
48 A Phase I/II Study of Sirolimus in Addition to Tacrolimus and Methotrexate for the Prevention of Acute-Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation From Unrelated Donors Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
49 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
50 Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation Completed NCT00055653 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;melphalan;methylprednisolone

Search NIH Clinical Center for Myelodysplastic/myeloproliferative Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :


imatinib
Imatinib mesylate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Myelodysplastic/myeloproliferative Neoplasm:
NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
Embryonic/Adult Cultured Cells Related to Myelodysplastic/myeloproliferative Neoplasm:
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152

Cochrane evidence based reviews: myelodysplastic-myeloproliferative diseases

Genetic Tests for Myelodysplastic/myeloproliferative Neoplasm

Anatomical Context for Myelodysplastic/myeloproliferative Neoplasm

Organs/tissues related to Myelodysplastic/myeloproliferative Neoplasm:

MalaCards : Bone Marrow, Myeloid, Bone, T Cells, Liver, Breast, Endothelial

Publications for Myelodysplastic/myeloproliferative Neoplasm

Articles related to Myelodysplastic/myeloproliferative Neoplasm:

(show top 50) (show all 156)
# Title Authors PMID Year
1
Myeloid neoplasm with ETV6::ACSl6 fusion: landscape of molecular and clinical features. 62
36069745 2022
2
Challenges in the interpretation of a germline TERT variant in a patient with juvenile myelomonocytic leukemia. 62
35927969 2022
3
Identification of cystic fibrosis transmembrane conductance regulator as a prognostic marker for juvenile myelomonocytic leukemia via the whole-genome bisulfite sequencing of monozygotic twins and data mining. 62
36247890 2022
4
Low-level somatic JAK2 V617F mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts, and thrombocytosis with co-mutated SF3B1 and CALR. 62
35920094 2022
5
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. 62
35379077 2022
6
Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement. 62
35461716 2022
7
Allogeneic stem cell transplantation for trisomy 8-positive myelodysplastic syndrome or myelodysplastic/myeloproliferative disease with refractory Behçet's disease: Case report and the review of literature. 62
35365826 2022
8
Clinical Application for Diagnosis of Myelodysplatic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis. 62
35443589 2022
9
The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm. 62
34471943 2022
10
Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. 62
34775472 2022
11
Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia. 62
35267643 2022
12
Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasm. 62
34551074 2022
13
Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts, thrombocytosis, and mutated JAK2/SF3B1 without anemia. 62
35050328 2022
14
CSF3R T618I mutant myelodysplastic/myeloproliferative neoplasm in the elderly: An age-related disease with unfavorable prognosis. 62
35795468 2022
15
The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm. 62
34270867 2021
16
Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia. 62
34580726 2021
17
Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea. 62
34590720 2021
18
Extramedullary myelodysplastic/myeloproliferative neoplasm (MDS/MPN) with ring sideroblasts and thrombocytosis. 62
33586865 2021
19
Cerebral localization of chronic myelomonocytic leukemia: a case report. 62
34303369 2021
20
Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia. 62
33660195 2021
21
A case of successful acyclovir desensitization in a bone marrow transplant patient. 62
32955996 2021
22
Development of a myelodysplastic/myeloproliferative neoplasm-unclassifiable in a patient with acute myeloid leukemia: a case report and literature review. 62
34057843 2021
23
JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone. 62
33373831 2021
24
Juvenile myelomonocytic leukemia-A comprehensive review and recent advances in management. 62
33796386 2021
25
Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches. 62
34868917 2021
26
Solving the Puzzle: The Diagnosis of Atypical Chronic Myeloid Leukemia, BCR-ABL1-Negative (aCML). 62
34491231 2021
27
Myelodysplastic syndrome transforming to atypical chronic myeloid leukemia shows changes in its mutation allele frequency and acquisition of new mutations. 62
34123720 2021
28
Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review. 62
35096623 2021
29
Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview. 62
34869027 2021
30
MDS/MPN-Unclassifiable with t(X;17)(q28;q21) and KANSL1-MTCP1/CMC4 Fusion Gene. 62
35038703 2021
31
NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity? 62
33255988 2020
32
[Spontaneous remission of cutaneous myeloid sarcoma]. 62
32854968 2020
33
Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome. 62
32798550 2020
34
Update on CML-Like Disorders. 62
32862848 2020
35
RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience. 62
32209330 2020
36
Successful prevention of severe allergic transfusion reactions with omalizumab. 62
32134497 2020
37
Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome. 62
32460983 2020
38
Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. 62
31776464 2020
39
Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant? 62
32460987 2020
40
Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term? 62
32460977 2020
41
A Rare Case of Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN) Involving Chronic Myeloid Leukemia: A Case Report and Literature Review. 62
32398637 2020
42
Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes. 62
31977035 2020
43
Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. 62
31750750 2020
44
Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. 62
31904665 2020
45
Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. 62
31511613 2020
46
CircRNAs Dysregulated in Juvenile Myelomonocytic Leukemia: CircMCTP1 Stands Out. 62
33490078 2020
47
Single-Center Experience With Epigenetic Treatment for Juvenile Myelomonocytic Leukemia. 62
32328464 2020
48
Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53. 62
33194542 2020
49
Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. 62
31017498 2019
50
Myelodysplastic/myeloproliferative neoplasm with eosinophilia as a manifestation of Li Fraumeni Syndrome. 62
31230491 2019

Variations for Myelodysplastic/myeloproliferative Neoplasm

Expression for Myelodysplastic/myeloproliferative Neoplasm

Search GEO for disease gene expression data for Myelodysplastic/myeloproliferative Neoplasm.

Pathways for Myelodysplastic/myeloproliferative Neoplasm



Pathways directly related to Myelodysplastic/myeloproliferative Neoplasm:

# Pathway Source
1 Signaling by cytosolic FGFR1 fusion mutants Reactome 66

Pathways related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 ABL1 ETV6 FLT3 HRAS JAK2 KIT
2
Show member pathways
13.77 PDGFRB NRAS NF1 KIT JAK2 HRAS
3 13.75 PTPN11 PDGFRB NRAS NF1 KIT JAK2
4
Show member pathways
13.62 PDGFRB NRAS KIT JAK2 HRAS FLT3
5
Show member pathways
13.38 CSF2 CSF3R FLT3 HRAS JAK2 KIT
6
Show member pathways
13.31 PTPN11 NRAS JAK2 HRAS FLT3 CSF3R
7
Show member pathways
13.19 PTPN11 PDGFRB NRAS KIT JAK2 HRAS
8
Show member pathways
13.08 PTPN11 PDGFRB NRAS NF1 KIT JAK2
9
Show member pathways
12.83 PDGFRB NRAS KIT JAK2 HRAS
10
Show member pathways
12.81 PDGFRB NRAS KIT JAK2 HRAS FLT3
11
Show member pathways
12.66 PTPN11 NRAS JAK2 HRAS FLT3
12 12.63 PTPN11 PDGFRB NRAS KIT JAK2 HRAS
13
Show member pathways
12.57 PTPN11 PDGFRB NRAS JAK2 HRAS
14 12.57 PDGFRB KIT HRAS FLT3 CSF2 ASXL1
15
Show member pathways
12.4 PTPN11 NRAS JAK2 HRAS
16 12.4 PDGFRB NRAS NF1 HRAS
17
Show member pathways
12.4 FLT3 HRAS NRAS PTPN11
18
Show member pathways
12.39 HRAS JAK2 NF1 PTPN11
19
Show member pathways
12.39 PTPN11 PDGFRB NRAS KIT HRAS
20
Show member pathways
12.38 PDGFRB NRAS KIT HRAS FLT3
21
Show member pathways
12.26 PTPN11 PDGFRB JAK2 ABL1
22
Show member pathways
12.26 PTPN11 PDGFRB NRAS KIT JAK2 HRAS
23
Show member pathways
12.2 PDGFRB NRAS HRAS CSF3R
24
Show member pathways
12.13 NRAS NF1 JAK2 HRAS
25 12 PDGFRB KIT JAK2 FLT3 ABL1
26
Show member pathways
11.97 PTPN11 NRAS HRAS FLT3 ETV6
27
Show member pathways
11.96 PTPN11 KIT JAK2 HRAS
28 11.95 KIT FLT3 CSF3R CSF2
29 11.93 HRAS NF1 NRAS PTPN11
30 11.92 PTPN11 KIT JAK2 HRAS
31 11.91 NRAS HRAS ABL1
32
Show member pathways
11.89 PTPN11 NRAS HRAS
33
Show member pathways
11.86 PTPN11 JAK2 HRAS
34
Show member pathways
11.85 PDGFRB KIT FLT3
35
Show member pathways
11.82 PTPN11 NRAS JAK2 HRAS
36 11.75 KIT FLT3 CSF2
37
Show member pathways
11.75 PTPN11 PDGFRB NRAS HRAS
38
Show member pathways
11.72 PTPN11 JAK2 CSF2
39
Show member pathways
11.72 HRAS JAK2 KIT NRAS PTPN11
40
Show member pathways
11.67 PDGFRB KIT ABL1
41
Show member pathways
11.65 NRAS NF1 HRAS
42
Show member pathways
11.6 PTPN11 JAK2 CSF3R
43 11.58 PTPN11 PDGFRB JAK2
44
Show member pathways
11.56 NRAS HRAS ETV6
45 11.5 PDGFRB JAK2 ABL1
46 11.49 PTPN11 PDGFRB NRAS NF1 KIT HRAS
47 11.48 PTPN11 JAK2 HRAS
48 11.47 PDGFRB NRAS HRAS
49 11.39 PDGFRB NRAS HRAS
50 11.33 NF1 HRAS CSF2

GO Terms for Myelodysplastic/myeloproliferative Neoplasm

Cellular components related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 U2AF complex GO:0089701 9.26 U2AF1L4 U2AF1
2 granulocyte macrophage colony-stimulating factor receptor complex GO:0030526 8.92 JAK2 CSF2

Biological processes related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 10.3 PDGFRB KIT JAK2 HRAS FLT3 CSF2
2 positive regulation of cell migration GO:0030335 10.27 CSF2 HRAS JAK2 KIT PDGFRB
3 protein autophosphorylation GO:0046777 10.18 ABL1 FLT3 JAK2 KIT PDGFRB
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 10.1 PDGFRB KIT JAK2 FLT3
5 positive regulation of fibroblast proliferation GO:0048146 10.09 PDGFRB HRAS ABL1
6 positive regulation of MAPK cascade GO:0043410 10.09 PDGFRB KIT JAK2 HRAS FLT3
7 phosphorylation GO:0016310 10.08 PDGFRB KIT JAK2 FLT3 ETNK1 ABL1
8 cytokine-mediated signaling pathway GO:0019221 10.07 CSF3R FLT3 JAK2 KIT PTPN11
9 positive regulation of MAP kinase activity GO:0043406 10.06 PDGFRB KIT HRAS FLT3
10 peptidyl-tyrosine phosphorylation GO:0018108 10.02 PDGFRB KIT JAK2 FLT3 ABL1
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.01 KIT JAK2 FLT3 CSF2
12 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 10 FLT3 KIT PDGFRB
13 myeloid cell differentiation GO:0030099 9.91 TET2 JAK2 CSF2
14 myeloid progenitor cell differentiation GO:0002318 9.9 KIT FLT3
15 positive regulation of leukocyte proliferation GO:0070665 9.89 JAK2 CSF2
16 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.88 PDGFRB ABL1
17 mast cell proliferation GO:0070662 9.86 NF1 KIT
18 granulocyte-macrophage colony-stimulating factor signaling pathway GO:0038157 9.85 JAK2 CSF2
19 regulation of MAPK cascade GO:0043408 9.75 PTPN11 NF1 KIT
20 positive regulation of phospholipase C activity GO:0010863 9.73 PDGFRB KIT HRAS
21 platelet-derived growth factor receptor signaling pathway GO:0048008 9.5 PTPN11 PDGFRB JAK2 ABL1
22 positive regulation of protein modification process GO:0031401 9.33 PDGFRB KIT FLT3
23 regulation of cell population proliferation GO:0042127 9.23 NF1 KIT HRAS FLT3 CSF2 ABL1

Molecular functions related to Myelodysplastic/myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.85 PDGFRB KIT FLT3
2 nucleotide binding GO:0000166 9.76 ABL1 ETNK1 FLT3 HRAS JAK2 KIT
3 SH2 domain binding GO:0042169 9.73 KIT JAK2 ABL1
4 pre-mRNA 3'-splice site binding GO:0030628 9.62 U2AF1L4 U2AF1
5 kinase activity GO:0016301 9.5 PDGFRB KIT JAK2 FLT3 ETNK1 ABL1
6 protein tyrosine kinase activity GO:0004713 9.32 PDGFRB KIT JAK2 FLT3 ABL1

Sources for Myelodysplastic/myeloproliferative Neoplasm

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....